Paper Details

  1. Home
  2. Paper Details

Clinical use and applications of histone deacetylase inhibitors in multiple myeloma.

Author: KumarShaji K, RamakrishnanVijay, TandonNidhi

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Histone deacetylase inhibitors (HDACi) have shown promising results in treating multiple myeloma, especially in combination with other therapies.
Paper Details　
Original Abstract of the Article :
The incorporation of various novel therapies has resulted in a significant survival benefit in newly diagnosed and relapsed patients with multiple myeloma (MM) over the past decade. Despite these advances, resistance to therapy leads to eventual relapse and fatal outcomes in the vast majority of pat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866749/

データ提供：米国国立医学図書館（NLM）

Histone Deacetylase Inhibitors: A Promising Weapon Against Multiple Myeloma

Multiple myeloma, a type of blood cancer, is a formidable foe. This research, published in [Journal name], investigates the potential of histone deacetylase inhibitors (HDACi) as a weapon against this disease. It's like a team of explorers searching for a hidden oasis in the vast desert of cancer research. The authors meticulously review the preclinical and clinical studies on HDACi, examining their anti-myeloma activity both as a single agent and in combination with other therapies. The study's findings reveal promising results, highlighting the potential for HDACi to improve outcomes for patients with multiple myeloma.

A New Era of Treatment Options

This study opens the door to a new era of treatment options for multiple myeloma patients. It's like discovering a new source of water in a parched land. The encouraging results suggest that HDACi, particularly when combined with other therapies, can effectively target the disease and prolong patient survival. This discovery holds tremendous potential for improving the lives of those battling this challenging cancer.

Navigating the Future of Multiple Myeloma Treatment

This research provides a roadmap for navigating the future of multiple myeloma treatment. It's like a compass guiding us through the vast desert of research and clinical practice. The study's findings highlight the potential for HDACi to become an integral part of treatment strategies, offering hope for patients and inspiring further research to optimize their use.

Dr.Camel's Conclusion

This research offers a ray of hope for patients battling multiple myeloma. HDACi, like a refreshing breeze in the desert, holds promise for improving treatment outcomes and ultimately, for improving the lives of those affected by this disease. It's a reminder that even in the face of challenging diseases, we can find innovative solutions and strive for a brighter future.

Date :
  1. Date Completed 2016-05-26
  2. Date Revised 2020-09-29
Further Info :

Pubmed ID

27226735

DOI: Digital Object Identifier

PMC4866749

Related Literature

Article Analysis
・Side Effects of panobinostat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.